Omega Healthcare Invts Stock (NYSE:OHI), Trade Ideas

Omega Healthcare Invts

Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).

Reit's,Concept,Is,Shown,By,Businessman.

Real Estate

NLCP

Build A Basket Of Well-Performing, High-Paying Dividend Stocks

Citibank

REIT

AMZN

EPRT

Citigroup Upgrades Six REITs In One Morning

A,Sign,Showing,An,Upward,Arrow,In,Front,Of,An

Analysts See Upside On These 3 REITs

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Investors Inc

OHIO ART CO by Ohio Art Company (The)

Ohio Valley Banc Corporation

The March consumer price index was another splash of cold water on investors' hopes that the Federal Reserve would be able to cut interest rates three times in 2024. When inflation numbers came in higher than expected for both core and noncore readings, it signaled that the Fed may have difficulty fulfilling its goal to reduce inflation to 2% annually.
As a result, stocks sold off and interest-sensitive real estate investment trusts (REITs) were hit hard. The dividend yields on many REITs have risen over the past few days.
In a best-of-both-worlds scenario, REIT investors would hold stocks that provide both appreciation and high-yield income. However, it's often difficult to find high-yielding stocks that aren't price laggards.
Take a look at five REITs that have demonstrated appreciation year to date (YTD) and have annual dividend yields between 7% and 9%. In addition, these five have diversification among several different REIT subsectors. Long-term investors can take advantage of present market sentiment to build a basket of these REITs while interest rates are still high.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
NewLake Capital Partners Inc. (OTCMARKETS: NLCP) is a New Canaan, Connecticut-based internally managed specialized industrial REIT with 31 properties totaling 1.7 million square feet across 12 states. NewLake Capital Partners specializes in triple-net leases to cannabis companies and provides capital to them when necessary. Its market cap is only $369.06 million.
NewLake was founded in 2019 and had its initial public offering (IPO) in August 2021. Its tenants include the largest companies in the cannabis industry, such as Curaleaf, Cresco Labs Inc. and Truelieve. As of March, it had a 100% occupancy rate with an average of 14.3 years remaining on its lease terms and 2.6% annual rent escalations on 15- to 20-year lease terms. &nbsp;&nbsp;
On March 14, Compass Point analyst Merrill Ross upgraded NewLake from Neutral to Buy and announced an $18.25 price target.&nbsp;
On March 11, NewLake announced its fourth-quarter operating results. Funds from operations (FFO) of $0.51 beat the estimates of $0.45 and its FFO of $0.48 in the fourth quarter of 2022. Revenue of $13.02 million beat the Wall Street estimate of $11.41 million and topped fourth-quarter 2022 revenue of $12.18 million.
On March 11, NewLake Capital Partners raised its quarterly dividend from $0.40 per share to $0.41 per share. The $1.64 annualized dividend per share yields 8.93%.
Trending
<ul>
<li>Want To Grow Your Wealth Passively? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
On April 2, the Florida Supreme Court approved an initiative to legalize recreational marijuana in Florida through a referendum on the November ballot. This should benefit NewLake, as it has one property leased to Curaleaf Holdings in Florida and has several other tenants with Florida locations.&nbsp;&nbsp;&nbsp;
Year to date, NewLake Capital Partners has had a total return of 16.03%. Keep in mind that as an over-the-counter (OTC) stock with an average daily volume of about 32,000 shares, it can be quite volatile.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, Maryland-based triple-net equity healthcare REIT that provides financing, capital and leasing to 69 operators of 862 senior housing, skilled nursing and assisted living facilities across 42 U.S. states and the United Kingdom. Omega Healthcare Investors has no part in the daily management of these facilities, which the operators run.
On March 22, Citigroup analyst Nicholas Joseph upgraded Omega Healthcare from Neutral to Buy and raised the price target from $32 to $35. On April 2, Truist Securities analyst Michael Lewis maintained a Hold on Omega and raised the price target from $31 to $32.
Omega has a total return of 1.62% YTD. The annualized dividend of $2.68 per share yields 8.73%.
Alexander's Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>) is a Paramus, New Jersey-based, mixed retail REIT that's externally managed by Vornado Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>), which also owns 33.1% of Alexander's stock. Alexanders has five large properties in the New York City metropolitan area.
On Feb. 12, Alexander's reported its fourth-quarter operating results. FFO of $4.99 was ahead of FFO of $4.03 in the fourth quarter of 2022. Revenue of $62.94 million topped $53.05 million in the fourth quarter of 2022.&nbsp;
Alexander's $18 per share annualized dividend yields 8.06%. Year to date, Alexander's has had a total return of 5.38%.
Highwoods Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is a Raleigh, North Carolina-based office REIT that owns, develops, acquires, leases and manages properties in the Southern cities of Atlanta; Charlotte and Raleigh, North Carolina; Dallas, Nashville, Tennessee; Orlando and Tampa, Florida; and Richmond, Virginia. It was founded in 1978 and had its IPO in 1994.
Highwoods owns 28.4 million square feet of office space. As of Dec. 31, its occupancy rate was 88.9%. Highwoods' tenant base is well diversified by industries, and its top 10 tenants include Bank of America Corp., the federal government, MetLife Inc., Bridgestone Americas Inc. and PPG Industries Inc. It also owns about 120 acres of land.
On Feb. 7, Highwoods Properties reported its fourth-quarter operating results. FFO of $0.99 per share trounced analyst estimates of $0.91 per share and was above FFO of $0.96 in the fourth quarter of 2022. Revenue of $206.86 million was slightly below the Street estimate of $207.83 million and declined from $211.71 million in the fourth quarter of 2022.&nbsp;
On March 28, Morgan Stanley analyst Ronald Kamdem maintained Highwoods Properties with an Underweight rating and raised the price target from $18 to $21.&nbsp;
On April 4, Highwoods announced it sold nine office buildings for gross proceeds of $79.4 million that will be used to reduce outstanding debt on its revolving credit facility.&nbsp;
Highwoods' annualized dividend of $2 per share yields 7.96%. Highwoods Properties' total return YTD is 9.82%.&nbsp;
Modiv Industrial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is a Reno, Nevada-based, internally managed diversified REIT with 42 single-tenant net-lease properties totaling 4.5 million square feet across 15 states. It has 39 industrial, four office and one retail property in a portfolio of about 30 tenants. Modiv Industrial was founded in 2015 and had its IPO date in February 2022.&nbsp;
Its portfolio has an excellent weighted average lease term (WALT) of 14 years and includes average annual rental increases of 2.5%. It has a 100% occupancy rate. Over the past year, Modiv has disposed of noncore office properties to focus more on an industrial portfolio.
On March 4, Modiv reported its fourth-quarter operating results. FFO of $0.40 per share beat the Street estimate of $0.38 per share. Revenue of $12.29 million just missed estimates of $12.14 million.&nbsp;
Modiv's annualized $1.15 dividend per share yields 7.27%. Its total return YTD is 17.23%.
&nbsp;Read Next:
<ul>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
<li>Searching for income? <a href="https://www.benzinga.com/go/3-high-yield-investments">3 High-Yield Investments To Boost Your Portfolio's Income</a>.</li>
</ul>

Truist Securities analyst Michael Lewis maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Hold and raises the price target from $31 to $32.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Omega Healthcare Invts, Raises Price Target to $32

The Federal Reserve's reassertion this week that despite recent gains in the consumer price index (CPI) and producer price index (PPI), it still envisions three rate cuts coming in 2024, sparking a rally in real estate investment trusts (REITs). On March 22, three analysts from Citigroup kept that enthusiasm going by upgrading a half dozen REITs and raising price targets on all six.
Take a look at the REITs receiving upgrades this week, along with some positives that each REIT has going for it. &nbsp;
Macerich Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) is a Santa Monica, California-based retail REIT that specializes in the acquisition, leasing and management of 44 regional town center malls across the U.S. Macerich was founded in 1972 and had its initial public offering (IPO) in 1994.
Macerich has recently developed new leadership. On March 1, Jackson Hsieh was appointed president and CEO of the company. On March 12, Hsieh and other Macerich senior executives celebrated 30 years of being in business as a public company by ringing the opening bell at the New York Stock Exchange.
On March 22, Citigroup analyst Nicholas Joseph upgraded Macerich from Sell to Neutral and raised the price target from $8 to $17.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, Maryland-based triple-net equity healthcare REIT that provides financing, capital and leasing to 69 operators among 862 senior housing, skilled nursing and assisted living facilities across 42 states throughout the U.S. and the United Kingdom. Omega Healthcare Investors has no part in the day-to-day management of these facilities, which are run by the operators.&nbsp;
On March 22, Citigroup analyst Nicholas Joseph upgraded Omega Healthcare from Neutral to Buy and raised the price target from $32 to $35.
On Feb. 26, Wells Fargo analyst Connor Siversky also upgraded Omega Healthcare Investors, from Equal-Weight to Overweight and raised the price target from $31 to $35.
Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) is a Tysons, Virginia-based hotel REIT with 43 hotels and resorts with over 26,000 rooms, located in prime U.S. markets from Hawaii to Massachusetts that have high barriers to entry. Park Hotels is a small-cap stock with a market cap of $3.737 billion. Its occupancy rate in the fourth quarter of 2023 was 71%, up from 69.5% in Q4 2022.
Park was established as an independent company in January 2017 following its spinoff from Hilton. In September 2019, Park acquired Chesapeake Lodging Trust to add premium-brand hotels and resorts in prime markets such as Miami, Boston, Los Angeles and San Francisco.
On March 22, Citigroup analyst Smedes Rose upgraded Park Hotels &amp; Resorts from Neutral to Buy and raised the price target from $14 to $20.
Several other analysts have recently come out with positive ratings on Park Hotels. Truist Securities has a Buy and $21 price target and Deutsche Bank has a Buy rating and a $24 price target on Park.
Tanger Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>), formerly called Tanger Factory Outlet Centers Inc., is a Greensboro, North Carolina-based retail REIT that owns 40 indoor shopping centers and outdoor factory outlet malls with 15.6 million square feet and over 3,000 stores across 20 states and in Canada. Tanger Factory Outlet Centers was founded in 1981 and had its IPO in May 1993. Tanger's occupancy rate at the end of 2023 was 97.3%.&nbsp;
Tanger was the second-leading REIT overall in 2023, with a total return of 63.58%, overcoming the popular idea that in-store retail shopping is in decline because of the popularity of Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and other online retailers. Its total return so far in 2024 is 5.09%.
On Feb. 15, Tanger reported excellent fourth-quarter operating results. Funds from operations (FFO) of $0.52 beat the estimate of $0.50. Revenue of $127.48 million beat the estimate of $119.04 million and was 9.46% above revenue from the fourth quarter of 2022 of $116.46 million. Additionally, full-year core FFO was announced in a range from $2.01-$2.09 per share, with a midpoint above the analyst consensus estimate of $2.03 per share.
On March 22, Citigroup analyst Michael Bilerman upgraded Tanger from Neutral to Buy and raised the price target from $30 to $33. Tanger continues to perform well and the Citigroup upgrade should help the share price as well. &nbsp;
Essential Properties Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) is a Princeton, New Jersey-based diversified REIT that owns and manages single-tenant properties with net leases for service-oriented and experience-based businesses. Essential Properties was founded in 2016 and has a market cap of $4.4 billion. It has a portfolio of 1,873 properties across 48 states. Its properties, which have a 99.8% occupancy rate, have a weighted average lease term (WALT) of 14 years.
On March 22, Citigroup analyst Nicholas Joseph upgraded Essential Properties from Neutral to Buy and raised the price target from $25 to $28.50. On March 13, B. Riley Securities also reiterated a Buy on Essential Properties and raised its price target from $27.50 to $29 per&nbsp;
Total occupancy and rent collection are extremely important aspects of a REIT, and from that standpoint, it's easy to see why analysts have upgraded Essential Properties' ratings and price targets this month.
American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) is a Calabasas, California-based residential REIT that purchases, develops, renovates and leases existing and new single-family homes as rental properties. American Homes 4 Rent was created in 2012 and in less than 12 years has built a portfolio of 58,470 single-family units across 21 states. Its largest concentration of homes is in the Southeastern U.S., where population growth has been explosive. Its IPO was in July 2013.
As of the fourth quarter of last year, American Homes 4 Rent had a same-home average occupied days of 96.2%.&nbsp;
On March 22, Citigroup analyst Nicholas Joseph upgraded American Homes 4 Rent from Neutral to Buy and raised the price target from $37 to $41.
Other analysts have also supported American Homes recently. On March 20, Mizuho analyst Haendel St. Juste maintained a Buy on American Homes and raised the price target from $37 to $39. On March 12, JMP Securities analyst Aaron Hecht maintained American Homes with an Outperform and raised the price target from $38 to $41.
<h2 class="wp-block-heading">Explore Opportunities Beyond REITs</h2>
While publicly traded REITs offer a convenient way to invest in real estate, we believe that some of the most compelling opportunities lie in the private market. Benzinga's <a href="https://www.benzinga.com/go/real-estate-screener">real estate offering screener</a> features a curated selection of private market real estate offerings from trusted platforms with a track record of strong returns.
Whether you&#8217;re an accredited or non-accredited investor, you can filter opportunities based on your investment criteria, including minimum investment, property type and target return. These offerings provide a unique chance to diversify your portfolio and tap into potential high-yield investments that are not available on public exchanges.
<a href="https://www.benzinga.com/go/real-estate-screener">Browse offerings</a>
Latest Private Market Offerings
<ul>
<li><a href="https://www.benzinga.com/alternative-investments/listing/qoz-fund-iii">QOZ Fund III</a>: Realize massive tax benefits investing in a portfolio of multifamily development projects with long-term growth potential located in designated Opportunity Zones.</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/gold-leaf-farming-lp">Golden Leaf Farming LP</a>: Top-tier almond and pistachio farms with a target cash yield of 13.8%</li>
</ul>
Discover these and other exclusive real estate investment opportunities on Benzinga's offering screener. Dive into the private market and uncover the potential for substantial returns beyond the public REIT market.

Throughout the last three months, 7 analysts have evaluated Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Omega Healthcare Invts, revealing an average target of $33.14, a high estimate of $36.00, and a low estimate of $30.00. Surpassing the previous average price target of $33.00, the current average has increased by 0.42%.
<img src="https://www.benzinga.com/files/images/story/2024/1711112451_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Omega Healthcare Invts by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Nate Crossett</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Omega Healthcare Invts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Omega Healthcare Invts's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Discovering Omega Healthcare Invts: A Closer Look</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Understanding the Numbers: Omega Healthcare Invts's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Omega Healthcare Invts's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 65.22%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Omega Healthcare Invts's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.98% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Omega Healthcare Invts's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.52%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omega Healthcare Invts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.42, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 7 Analyst Ratings For Omega Healthcare Invts

Citigroup analyst Nicholas Joseph upgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Neutral to Buy and raises the price target from $32 to $35.

Upgrades

Citigroup Upgrades Omega Healthcare Invts to Buy, Raises Price Target to $35

As an investor, it's always a thrill to see positive news on one of your stocks that is likely to increase the share price. The news might be a dividend raise, a good earnings report, a new product, service or alliance or an upgrade from an analyst at a prestigious brokerage or bank.
Take a look at three real estate investment trusts (REITs) that recently received analyst upgrades to begin a new week. All three posted meaningful fourth-quarter earnings and received price target increases from the analysts that are sure to boost the share prices.&nbsp;
National Health Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a Murfreesboro, Tennessee-based healthcare REIT that specializes in sale-leaseback, joint-venture, mortgage and mezzanine financing of senior housing and medical investments. Its portfolio of 194 properties consists of senior housing, skilled nursing facilities and specialty hospitals. National Health Investors was incorporated in 1991.
On Feb. 26, Wells Fargo analyst Connor Siversky upgraded National Health Investors from Equal-Weight to Overweight and raised the price target from $55 to $63.
It's easy to see why the analyst upgraded it. On Feb. 20, National Health Investors issued its fourth-quarter operating results. Funds from operations (FFO) of $1.09 per share beat the Street estimate of $1.07 per share and was well above its fourth-quarter 2022 FFO of $0.87 per share. Revenue of $79.47 million was also ahead of the estimate of $78.44 million and above fourth-quarter 2022 revenue of $70.67 million. Full-year FFO guidance in a range from $4.31-$4.37 with a midpoint of $4.34 came in just a penny shy of the $4.33 estimate.
National Health Investors also announced it will pay a first-quarter dividend of $0.90 per share on May 3 to stockholders as of March 28. The annual $3.60 dividend yields 6.2%.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, Maryland-based triple-net equity healthcare REIT that provides financing, capital and leasing to 69 operators among 862 senior housing, skilled nursing and assisted living facilities across 42 states in the U.S. and the United Kingdom. Omega Healthcare Investors has no part in the day-to-day management of these facilities, which are run by the operators.
On Feb. 26, Wells Fargo analyst Siversky upgraded Omega Healthcare Investors from Equal-Weight to Overweight and raised the price target from $31 to $35.
On Feb. 7, Omega Healthcare also posted strong fourth-quarter operating results. Although FFO of $0.68 per share slipped from $0.73 in the fourth quarter of 2022, it still beat the estimate of $0.67 per share. Revenue of $239.32 million beat the estimate of $233.82 million and was a 65.22% increase from fourth-quarter 2022 revenue of $144.85 million.
Since the release of the earnings report, Omega Healthcare is up about 11%.
AvalonBay Communities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) is a residential REIT that acquires, develops and manages multifamily communities. As of Dec. 31, AvalonBay Communities owned approximately 90,669 apartments directly or indirectly in 299 communities across 12 states and Washington, D.C.&nbsp;
On Feb. 26, Morgan Stanley analyst Adam Kramer upgraded AvalonBay Communities from Equal-Weight to Overweight and raised the price target from $175 to $191.50. On Feb. 22, Goldman Sachs reinstated AvalonBay at Neutral with a $191 price target.
On Jan. 31, AvalonBay posted its fourth-quarter operating results. Core FFO of $2.74 was in line with estimates but up from $2.59 in the fourth quarter of 2022. Revenue of $702.7 million beat the estimates of $700.16 million and was 5.45% above the revenue of $666.39 million in the fourth quarter of 2022.
On Feb. 7, Jim Cramer of CNBC's "Mad Money" also recommended AvalonBay, saying, "I think AvalonBay right here is done going down." Although the stock did drop another $4 before bottoming, it has rebounded and was recently about $2 above its price when he made that call.
Explore Opportunities Beyond REITs
While publicly traded REITs offer a convenient way to invest in real estate, we believe that some of the most compelling opportunities lie in the private market. Benzinga's <a href="https://www.benzinga.com/alternative-investments/real-estate">real estate offering screener</a> features a curated selection of private market real estate offerings from trusted platforms with a track record of strong returns.
Whether you&#8217;re an accredited or non-accredited investor, you can filter opportunities based on your investment criteria, including minimum investment, property type and target return. These offerings provide a unique chance to diversify your portfolio and tap into potential high-yield investments that are not available on public exchanges.
<a href="https://www.benzinga.com/alternative-investments/real-estate">Browse offerings</a>
Latest Private Market Offerings
<ul>
<li><a href="https://www.benzinga.com/alternative-investments/listing/horizon-village">Horizon Village</a>: Grocery-anchored shopping center located in Phoenix, AZ, with a target return of 12%.</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/gold-leaf-farming-lp">Golden Leaf Farming LP</a>: Top-tier almond and pistachio farms with a target cash yield of 13.8%</li>
</ul>

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.83, a high estimate of $36.00, and a low estimate of $30.00. This current average represents a 1.26% decrease from the previous average price target of $33.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1708963252_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Omega Healthcare Invts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Nate Crossett</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Omega Healthcare Invts's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Omega Healthcare Invts's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Get to Know Omega Healthcare Invts Better</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>A Deep Dive into Omega Healthcare Invts's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Omega Healthcare Invts's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 65.22%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Omega Healthcare Invts's net margin excels beyond industry benchmarks, reaching 22.98%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Omega Healthcare Invts's ROE excels beyond industry benchmarks, reaching 1.52%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.59%, the company showcases effective utilization of assets.
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below the industry average at 1.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Have This To Say About Omega Healthcare Invts

Wells Fargo analyst Connor Siversky upgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Equal-Weight to Overweight and raises the price target from $31 to $35.

Wells Fargo Upgrades Omega Healthcare Invts to Overweight, Raises Price Target to $35

Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEAK#NYSE">PEAK</a>), Omega Healthcare Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), and Ventas Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) are at the forefront of healthcare REITs, uniquely positioned to benefit from partnerships and tenancies with pharmaceutical giants like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). As Pfizer continues to expand its research and healthcare services, these REITs could see significant growth opportunities, leveraging the pharmaceutical industry&#8217;s evolving needs.
<h2 class="wp-block-heading">Don't Miss:</h2>
<ul>
<li>Investing in real estate just got a whole lot simpler. This<a href="https://www.benzinga.com/money/dara-khosrowshahi-backed-startup-lets-you-become-a-landlord-with-100"> Dara Khosrowshahi-backed startup</a> will allow you to become a landlord in just 10 minutes, and you only need $100.</li>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. A platform backed by industry giant Marcus &amp; Millichap is changing that,<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> allowing individuals to invest in commercial real estate with as little as $5,000. </a></li>
</ul>
Healthpeak Properties, with its investment in life sciences properties and a dividend of 7%, offers spaces that could be pivotal for companies like Pfizer, focusing on research and development. PEAK&#8217;s state-of-the-art facilities are designed to support the complex requirements of pharmaceutical research, offering an environment conducive to innovation. A partnership or tenancy with Pfizer would not only bring prestige to Healthpeak&#8217;s portfolio but also solidify its position as a leader in life sciences real estate.
Omega Healthcare Investors, specializing in long-term care facilities with a dividend of 9%, presents an opportunity for collaboration with Pfizer, particularly in areas like clinical trials and patient care programs. With Pfizer&#8217;s ongoing development of treatments and vaccines, facilities within OHI&#8217;s portfolio could serve as critical sites for patient-centric research and trials, enhancing Omega&#8217;s role in supporting healthcare delivery and pharmaceutical advancements.
Ventas Inc., with its diverse healthcare real estate portfolio and a dividend of 4%, including research and medical office buildings, aligns well with Pfizer&#8217;s comprehensive approach to healthcare. Ventas&#8217;s facilities could host Pfizer&#8217;s research initiatives, administrative offices, or patient care services, making VTR a strategic real estate partner for Pfizer as it seeks to expand its footprint in key healthcare markets.
<h2 class="wp-block-heading">Read Next:</h2>
<ul>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. A platform backed by industry giant Marcus &amp; Millichap is changing that,<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> allowing individuals to invest in commercial real estate with as little as $5,000. </a></li>
<li>Collecting passive income from real estate just got a whole lot simpler. A new<a href="https://www.benzinga.com/money/dara-khosrowshahi-backed-startup-lets-you-become-a-landlord-with-100"> real estate fund backed by Dara Khosrowshahi</a> gives you instant access to a diversified portfolio of rental properties, and you only need $100 to get started.</li>
</ul>
Image credit: Shutterstock

PEAK

Pfizer's Expansion Sparks Boom for these Healthcare REITs

Investors looking to own winning stocks need to know which sectors are outperforming other sectors when making purchase decisions. With real estate investment trusts (REITs), subsectors go in and out of favor based on economic news, earnings and technical indicators such as being overbought or oversold.
A few months ago, office REITs were trouncing other subsectors. However, over the last week, healthcare REITs have emerged as the new leader among REITs. The healthcare REIT sub sector was not a great overall performer in 2023, but things may be turning around in 2024.
Take a look at four healthcare REITs that have shown strong performance since the close of trading on Feb. 5.
Medical Properties Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) is a Birmingham, Alabama-based healthcare REIT that owns and operates 441 general acute care and other properties across the U.S. and in nine other countries, including locations in Europe and Australia. It has a portfolio valued at $19 billion, of which about 64% are general acute care hospitals. About two-thirds of its properties are in the United States.&nbsp;
Medical Properties Trust was one of the worst performing of all REITs in January, following its update on its largest tenant, Steward Health Care System. The share price fell more than 30% after Medical Properties said it's accelerating its efforts to recover uncollected rents from the fourth quarter of 2023 and outstanding loan obligations from Steward. Medical Properties also agreed to fund a new $60 million bridge loan to Steward, secured by preexisting collateral plus a new second lien on Steward's managed care business.
In addition, Steward said it would explore the possible sale or re-tenanting of certain hospital operations along with the divestiture of non-core operations. At the end of 2023, Steward still owed approximately $50 million to Medical Properties Trust.
Lately, Medical Properties Trust has been a hot stock, up 10.73% since Feb. 5. There has been no news or analyst upgrades, and its fourth-quarter earnings don't come out until Feb. 21, so perhaps it's just an oversold bounce.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, Maryland-based triple-net equity healthcare REIT that provides financing, capital and leasing to 69 operators of 862 senior housing, skilled nursing and assisted living facilities across 42 states throughout the U.S. and the United Kingdom. Omega Healthcare Investors has no part in the day-to-day management of these facilities, which are run by the operators.
On Jan. 30, Deutsch bank analyst Omotayo Okusanya initiated coverage on Omega Healthcare Investors with a Buy rating and announced a price target of $36.
On Feb. 7, Omega Healthcare reported its fourth-quarter operating results. Funds from operations (FFO) of $0.68 per share beat the analysts' estimate of $0.67 per share but was below FFO of $0.73 in the fourth quarter of 2022. Revenue of $239.32 million beat the estimates of $233.82 million and the fourth-quarter 2022 revenue of $144.85 million by 65.22%.
On the strength of its earnings report, Omega Healthcare is up 10.3% since Feb. 5.
Caretrust REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) is a San Clemente, California-based healthcare REIT, founded in 2013, that owns and leases senior housing, skilled nursing facilities (SNF) and assisted living facilities (ALF). As of Dec. 31, its long-term net-lease portfolio consisted of 207 properties across 25 states with 23 property operators. Skilled nursing facilities account for 71.5% of its portfolio, 8.8% is senior housing and the remaining 19.7% is multiservice campus.
On Jan. 31, RBC Capital Markets analyst Michael Carroll maintained an Outperform rating on Caretrust and lowered the price target from $25 to $24.
On Feb. 8, Caretrust reported fourth-quarter operating results. FFO of $0.36 was in line with estimates but a decrease from FFO of $0.38 in the same quarter a year ago. But revenue of $59.73 million was 11.61% above analyst estimates of $53.52 million and a 15.29% increase over revenue of $51.81 million in the fourth quarter of 2022.
Since Feb. 5, Caretrust has risen 10.32%. Investors were impressed with the fourth-quarter results.
Sabra Health Care REIT Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is an Irvine, California-based healthcare REIT that as of Sept. 30 has 410 investments across the U.S. Its portfolio consists of senior nursing facilities (SNF), senior housing, behavioral health and specialty hospitals with eight-year weighted average lease terms (WALT). Signature Healthcare is its largest tenant, with a rent concentration of 9%.
Sabra CEO Rick Matros recently told analysts that occupancy gains and easing labor pressures are driving rent coverage higher and Medicaid reimbursements have also been increasing. Sabra sold 13 SNFs and two senior housing facilities during the third quarter with net proceeds used to reduce the outstanding balance on Sabra's revolving credit facility.
On Jan. 30, Deutsch bank analyst Omotayo Okusanya initiated coverage on Sabra Health Care with a Buy rating and announced a price target of $21. The following day, Jenny Harrington of Gilman Hill Asset Management also recommended it on CNBC.
Sabra Health Care has climbed 7% since Feb. 5.
Explore Opportunities Beyond REITs
While publicly traded REITs offer a convenient way to invest in real estate, we believe that some of the most compelling opportunities lie in the private market. Benzinga's <a href="https://www.benzinga.com/alternative-investments/real-estate">real estate offering screener</a> features a curated selection of private market real estate offerings from trusted platforms with a track record of strong returns.
Whether you&#8217;re an accredited or non-accredited investor, you can filter opportunities based on your investment criteria, including minimum investment, property type and target return. These offerings provide a unique chance to diversify your portfolio and tap into potential high-yield investments that are not available on public exchanges.
<a href="https://www.benzinga.com/alternative-investments/real-estate">Browse offerings</a>
Latest Private Market Offerings
<ul>
<li><a href="https://www.benzinga.com/alternative-investments/listing/horizon-village">Horizon Village</a>: Grocery-anchored shopping center located in Phoenix, AZ, with a target return of 12%.</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/coop-at-eado">COOP @ EaDo</a>: Class A multifamily development with a 99-year property tax exemption and a target return of 20.9%</li>
<li><a href="https://www.benzinga.com/alternative-investments/listing/multi-family-portfolio-fund">Multi-Family Portfolio Fund</a>: Portfolio of existing class &#8216;B &amp; C&#8217; multi-family assets in the West &amp; South Western United States and a minimum investment of only $500.</li>
</ul>
Discover these and other exclusive real estate investment opportunities on Benzinga's offering screener. Dive into the private market and uncover the potential for substantial returns beyond the public REIT market.

CTRE

SBRA

Healthcare REITs Showing Strong Performance In February

WIIM

Omega Healthcare shares are trading higher after the company reported better-than-expected Q4 financial results.

Exane BNP Paribas analyst Nate Crossett upgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Underperform to Neutral and announces $30 price target.

Exane BNP Paribas Upgrades Omega Healthcare Invts to Neutral, Announces $30 Price Target

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.67 by 1.49 percent. The company reported quarterly sales of $239.32 million which beat the analyst consensus estimate of $233.82 million by 2.35 percent. This is a 65.22 percent increase over sales of $144.85 million the same period last year.

Earnings

Earnings Beats

Omega Healthcare Invts Q4 2023 FFO $0.68 Beats $0.67 Estimate, Sales $239.32M Beat $233.82M Estimate

ACLS

ADNT

ALCO

APPS

ARCC

ASGN

ASND

AVXL

AZTA

BABA

BARK

BERY

BLBD

CDAY

CENT

CENTA

CFLT

CMRE

COTY

CRTO

CSGS

EEFT

ENTA

EQNR

FLNC

FLNG

FORM

FOXA

GEOS

GPRE

GPRO

HAIN

INTR

MCFT

MKSI

MPWR

MSGE

MTRX

NBIX

NOTV

NTGR

NVST

NWSA

OESX

ORLY

OSCR

PAHC

Earnings Scheduled For February 7, 2024

When analysts initiate coverage on a stock, it means the analyst will begin to provide research on a stock and make investment recommendations on it for the first time. This move is important because it typically leads to an increase in trading volume and interest among investors. It can ultimately help shares of those stocks to move higher, depending upon the rating given.
Usually, the analyst will start with two or three similar stocks at one time. But every once in a while, an analyst will begin coverage on a larger group within a subsector.
This week, on January 30, 2024, was one of those instances, as ten healthcare real estate investment trusts (REITs) had coverage initiated by a single analyst, but only six of the ten were rated "Buys."&nbsp;
Sabra Health Care REIT Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) is an Irvine, California-based healthcare REIT that owns 410 properties across the U.S. Its portfolio consists of Senior Nursing Facilities (SNF), Senior Housing, Behavioral Health and Specialty Hospitals with eight-year weighted average lease terms (WALT). Signature Healthcare is its largest tenant, with a rent concentration of 9%.
Sabra CEO Rick Matros recently told analysts that occupancy gains and easing labor pressures are driving rent coverage higher and Medicaid reimbursements are likely to increase. Thirteen SNF and two Senior Housing facilities were sold during Q3 2023 with the net proceeds used to reduce the outstanding balance on Sabra's revolving credit facility.
On January 30, Deutsch bank analyst Omotayo Okusanya initiated coverage on Sabra Health Care with a Buy rating and announced a price target of $21. Earlier in the month, Mizuho analyst Vikram Malhotra also maintained a Buy rating on Sabra Health, while raising the target price from $15 to $17.
Sabra Health Care has a total return of -5.00% in 2024.
<h2 class="wp-block-heading">Don't Miss:</h2>
<ul>
<li>Investing in real estate just got a whole lot simpler. This<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> Jeff Bezos-backed startup</a> will allow you to become a landlord in just 10 minutes, and you only need $100.</li>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to these <a href="https://www.benzinga.com/money/godwin-capital-notes">high-yield commercial real estate notes that pay a fixed 10% &#8211; 12%.</a></li>
</ul>
Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is a Toledo, Ohio, based healthcare REIT that owns interests in housing for seniors, post-acute communities and outpatient medical properties. It does this by providing capital to the operators who run these facilities. Welltower was founded in 1970 under the original name of Health Care Fund and was incorporated as a REIT in 1985. Welltower is a member of the S&amp;P 500.
Welltower has a total portfolio of 2017 properties, consisting of Senior Housing, Outpatient Medical and Long-Term/Post-Acute care across the U.S. The average age of the facilities is 20 years.
Deutsch bank analyst Omotayo Okusanya initiated coverage on Welltower with a Buy rating and announced a $115 price target. Earlier in the month Keybanc analyst Todd Thomas had maintained an overweight rating while raising the price target from $90 to $95.
Welltower was one of the 15 best-performing REITs of 2023, with a total return of 39.64%, but thus far in 2024 the total return is -3.40%.
Ventas Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) is a Chicago-based diversified healthcare REIT with approximately 1,400 properties that include senior living communities, life science, research and innovation properties, medical office buildings, outpatient facilities and skilled nursing facilities. Ventas has been in business for over 20 years and is a member of the S&amp;P 500.
Deutsch bank analyst Omotayo Okusanya initiated coverage on Ventas with a Buy rating and announced a price target of $60. On January 16, 2023, Bank of America Securities analyst Joshua Dennerlein upgraded Ventas from Neutral to Buy and raised the price target from $48 to $53.
Ventas has a total return of -4.90% in 2024.
National Health Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a Murfreesboro, Tennessee-based healthcare REIT that specializes in sale-leaseback, joint-venture, mortgage and mezzanine financing of senior housing and medical investments. Its portfolio of 192 properties consists of independent living, assisted living, memory care communities, skilled nursing facilities, medical office buildings and specialty hospitals. National Health Investors was incorporated in 1991.
Deutsch bank analyst Omotayo Okusanya initiated coverage on National Health Investors with a Buy rating and announced a price target of $6.
National Health Investors has a total return in 2024 of -2.66%.
Omega Healthcare Investors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a Hunt Valley, MD triple-net equity healthcare REIT that provides financing, capital and leasing to 66 different operators in 883 senior housing, skilled nursing and assisted living facilities across 42 states throughout the U.S. and the United Kingdom. Omega Healthcare Investors has no part in the day-to-day management of these facilities, which are run by the operators.
Deutsch bank analyst Omotayo Okusanya initiated coverage on Omega Healthcare Investors with a Buy rating and announced a price target of $36.
Omega Healthcare has a total return of -5.02% in 2024.
Three other healthcare REITs, Healthcare Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>), LTC Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) and Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEAK#NYSE">PEAK</a>) also had coverage initiated on January 30 and received Hold Ratings. Price targets for the three were $18, $34 and $21 respectively.
Medical Properties Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>), which is already down 36% in 2024, was tagged with a Sell rating and a price target of $2.
Healthcare REITs have shown improvements in occupancy and ability to restructure leases with operators, but not all healthcare REITs have been equal in making these changes, and that is reflected in the various ratings by Okusanya.
Investors should keep in mind that analysts are only correct about 50% of the time, and it's best for investors to perform their own due diligence before making purchase or sell transactions.
<h2 class="wp-block-heading">Read Next:</h2>
<ul>
<li>Elon Musk has reportedly bought 6,000 acres of land just outside of Austin.<a href="https://www.benzinga.com/real-estate/23/05/32537165/elon-musk-is-bullish-on-austin-heres-how-to-invest-in-the-citys-growth-before-he-floods-it-with-new"> Here&#8217;s how to invest in the city&#8217;s growth</a> before he floods it with new tech workers.</li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/3-high-yield-investments-boost-income">Here are 3 high-yield investments to add significant income to your portfolio</a>.</li>
<li>Collecting passive income from real estate just got a whole lot simpler. A new<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> real estate fund backed by Jeff Bezos</a> gives you instant access to a diversified portfolio of rental properties, and you only need $100 to get started.</li>
</ul>

$LTC

WELL

Analyst Initiates Coverage On 10 Healthcare REITs, But Which Ones Are Buys?

Across the recent three months, 5 analysts have shared their insights on Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.0, a high estimate of $36.00, and a low estimate of $31.00. A 2.94% drop is evident in the current average compared to the previous average price target of $34.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1706623261_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Omega Healthcare Invts among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Omega Healthcare Invts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Omega Healthcare Invts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Omega Healthcare Invts's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>All You Need to Know About Omega Healthcare Invts</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. The company maintains dual goals of increasing its returns to investors while also maintaining a high level of care for residents. Omega works to obtain contractual rent escalations under long-term leases, along with fixed-rate mortgage loans. The company considers merger and acquisition investment as a component of its operational growth strategy.
<h3>Unraveling the Financial Story of Omega Healthcare Invts</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Omega Healthcare Invts showcased positive performance, achieving a revenue growth rate of 1.09% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Omega Healthcare Invts's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 37.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.51%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Omega Healthcare Invts's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.97% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below the industry average at 1.44, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Omega Healthcare Invts Through 5 Analysts

Deutsche Bank analyst Omotayo Okusanya initiates coverage on Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Buy rating and announces Price Target of $36.

Initiation

Deutsche Bank Initiates Coverage On Omega Healthcare Invts with Buy Rating, Announces Price Target of $36

B of A Securities analyst Joshua Dennerlein downgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Buy to Neutral and lowers the price target from $33 to $31.

Downgrades

B of A Securities Downgrades Omega Healthcare Invts to Neutral, Lowers Price Target to $31

Mizuho analyst Haendel St. Juste maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Buy and lowers the price target from $35 to $34.

Mizuho Maintains Buy on Omega Healthcare Invts, Lowers Price Target to $34

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. raised Karuna Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krtx#NASDAQ">KRTX</a>) price target from $300 to $330. HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgraded the stock from Buy to Neutral. Karuna Therapeutics shares jumped 47.7% to close at $317.85 on Friday. <a href="https://www.benzinga.com/quote/KRTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) from $17 to $1. B of A Securities analyst Jason Zemansky downgraded the stock from Buy to Underperform. AlloVir shares fell 67.2% to close at $0.7654 on Friday. <a href="https://www.benzinga.com/quote/ALVR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James boosted the price target for Farmland Partners Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fpi#NYSE">FPI</a>) from $14 to $15. Raymond James analyst Buck Horne maintained an Outperform rating. Farmland Partners shares gained 1.3% to close at $12.76 on Friday. <a href="https://www.benzinga.com/quote/FPI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut the price target for Paychex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payx#NASDAQ">PAYX</a>) from $130 to $125. Citigroup analyst Peter Christiansen maintained a Neutral rating. Paychex shares rose 0.8% to close at $119.86 on Friday. <a href="https://www.benzinga.com/quote/PAYX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed the price target for Equillium, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eq#NASDAQ">EQ</a>) from $4.5 to $4. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Equillium shares fell 0.3% to close at $0.6570 on Friday. S<a href="https://www.benzinga.com/quote/EQ/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Truist Securities cut Omega Healthcare Investors, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ohi#NYSE">OHI</a>) price target from $34 to $31. Truist Securities analyst Michael Lewis maintained a Hold rating. Omega Healthcare Investors shares fell 0.1% to close at $30.70 on Friday. <a href="https://www.benzinga.com/quote/OHI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Huntington Bancshares Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hban#NASDAQ">HBAN</a>) price target from $13 to $15. Raymond James analyst David Long maintained a Strong Buy rating. Huntington Bancshares shares gained 0.2% to close at $12.66 on Friday. <a href="https://www.benzinga.com/quote/HBAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush boosted Cognizant Technology Solutions Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctsh#NASDAQ">CTSH</a>) price target from $75 to $85. Wedbush analyst Moshe Katri maintained an Outperform rating. Cognizant Technology shares gained 1.3% to close at $75.15 on Thursday. <a href="https://www.benzinga.com/quote/CTSH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson increased Modine Manufacturing Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mod#NYSE">MOD</a>) price target from $60 to $80. DA Davidson analyst Matt Summerville maintained a Buy rating. Modine Manufacturing shares gained 1.5% to close at $58.67 on Friday. <a href="https://www.benzinga.com/quote/MOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital increased CMS Energy Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cms#NYSE">CMS</a>) price target from $61 to $64. BMO Capital analyst James Thalacker maintained an Outperform rating. CMS Energy shares gained 0.6% to close at $57.23 on Friday. S<a href="https://www.benzinga.com/quote/CMS/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/23/12/36358246/nike-posts-downbeat-sales-joins-netease-and-other-big-stocks-moving-lower-in-fridays-pre-market-sess"> Nike Posts Downbeat Sales, Joins NetEase And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session </a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

ALVR

CTSH

HBAN

KRTX

PAYX

Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday

Ventas: The Silver Tsunami Vs. A Decade Of Underperformance

Omega Healthcare Investors: How Safe Is The 9% Yield

Showcasing Seeking Alpha's March 2024 New Analysts

Healthpeak Properties: A Quality Healthcare REIT That Should Get Back To Dividend Growth

Omega Healthcare: Better Options In The Healthcare Space For Dividend Investors

Omega Healthcare logs 7th straight losing session

Omega Healthcare Investors declares $0.67 dividend

A Hawkish Pivot

I Am Buying This Fat 7.2% Yielding Trust Hand Over Fist

March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys